Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters

被引：0

作者：

Diekmann, F. ^{[1
]}

Tedesco-Silva, H. ^{[2
]}

Peddi, V. ^{[3
]}

Sanchez-Fructoso, A. ^{[4
]}

Marder, B. ^{[5
]}

Russ, G. ^{[6
]}

Flynn, A. ^{[7
]}

Hahn, C. ^{[7
]}

Li, H. ^{[7
]}

Tortorici, M. ^{[7
]}

Schulman, S. ^{[7
]}

机构：

[1] Hosp Clin Barcelona, Barcelona, Spain

[2] Hosp Rim & Hipertensao, Sao Paulo, Brazil

[3] Calif Pacific Med Ctr, San Francisco, CA USA

[4] Hosp Clin San Carlos, Madrid, Spain

[5] Presbyterian St Lukes Med Ctr, Denver, CO USA

[6] Royal Adelaide Hosp, Adelaide, SA 5000, Australia

[7] Pfizer, Collegeville, PA USA

来源：

AMERICAN JOURNAL OF TRANSPLANTATION | 2014年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

B969

引用

页码：540 / 541

页数：2

共 50 条

[1] Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters.
Diekmann, F.
Tedesco-Silva, H.
Peddi, V.
Sanchez-Fructoso, A.
Marder, B.
Russ, G.
Flynn, A.
Hahn, C.
Li, H.
Tortorici, M.
Schulman, S.
TRANSPLANTATION, 2014, 98 : 540 - 541
[2] PLANNED TRANSITION FROM TACROLIMUS TO SIROLIMUS VERSUS CONTINUED TACROLIMUS IN RENAL ALLOGRAFT PATIENTS
Morales, Jose M.
Tedesco-Silva, Helio
Peddi, V. R.
Russ, Graeme R.
Marder, Bradley A.
Hahn, Carolyn M.
Li, Huihua
Flynn, Alison
Schulman, Seth L.
TRANSPLANT INTERNATIONAL, 2013, 26 : 81 - 81
[3] Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft
Tedesco-Silva, H.
Peddi, V.
Sanchez-Frutuoso, A.
Marder, B.
Russ, G.
Flynn, A.
Hahn, C.
Tortorici, M.
Schulman, S.
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 538 - 538
[4] Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft.
Tedesco-Silva, H.
Peddi, V.
Sanchez-Frutuoso, A.
Marder, B.
Russ, G.
Flynn, A.
Hahn, C.
Tortorici, M.
Schulman, S.
TRANSPLANTATION, 2014, 98 : 538 - 538
[5] Interim Results from an Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Cardiovascular Safety
Tedesco-Silva, H.
Peddi, V. R.
Sanchez-Fructoso, A.
Russ, G.
Marder, B.
Hahn, C.
Li, H.
Flynn, A.
Schulman, S.
TRANSPLANTATION, 2012, 94 (10) : 142 - 142
[6] Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Demographics and Interim Safety Results.
Tedesco-Silva, H.
Peddi, R.
Russ, G.
Marder, B.
Hahn, C.
Li, H.
Flynn, A.
Schulman, S.
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 337 - 337
[7] Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients
Tedesco-Silva, Helio
Peddi, V. Ram
Sanchez-Fructuoso, Ana
Marder, Brad A.
Russ, Graeme R.
Diekmann, Fritz
Flynn, Alison
Hahn, Carolyn M.
Li, Huihua
Tortorici, Michael A.
Schulman, Seth L.
TRANSPLANTATION DIRECT, 2016, 2 (04):
[8] Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients
Russ, GR
Campbell, S
Chadban, S
Eris, J
O'Connell, P
Pussell, B
Walker, R
TRANSPLANTATION PROCEEDINGS, 2003, 35 (3A) : 115S - 117S
[9] Immunoregulatory effects of sirolimus vs. tacrolimus treatment in kidney allograft recipients
Gong, Nianqiao
Chen, Zhishui
Wang, Jing
Fang, Aifang
Li, Yonghai
Xiang, Ying
Ming, Changsheng
Zhang, Weijie
CELLULAR IMMUNOLOGY, 2015, 297 (02) : 87 - 93
[10] Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients
Hakeam, Hakeam A.
Al-Jedai, Ahmed H.
Raza, Syed M.
Hamawi, Khaled
ANNALS OF TRANSPLANTATION, 2008, 13 (02) : 46 - 53

← 1 2 3 4 5 →